Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-07
2011-06-07
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S925000, C536S123100
Reexamination Certificate
active
07956047
ABSTRACT:
The present invention comprises the use of chondroitin sulphate (CS-E) or an active fragment thereof for the treatment of diseases or conditions related to collagen fibril formation. Said compounds can be administrated either by oral, topical, injectable or by any other suitable route.
REFERENCES:
patent: 5929050 (1999-07-01), Petito
patent: 5955578 (1999-09-01), Pierschbacher et al.
patent: 6162787 (2000-12-01), Sorgente et al.
patent: 6372794 (2002-04-01), Nimni
patent: 6599888 (2003-07-01), Derrieu et al.
patent: 2003/0069205 (2003-04-01), Roufa et al.
patent: 2493639 (2004-02-01), None
patent: 10-120577 (1998-05-01), None
patent: 2004-059506 (2004-02-01), None
patent: 2004-210715 (2004-07-01), None
patent: 2216332 (2003-11-01), None
patent: WO 91/15216 (1991-10-01), None
patent: WO 01/93846 (2001-12-01), None
patent: WO 02/33085 (2002-04-01), None
patent: WO 2005/102362 (2005-11-01), None
Boyd, J. (2007) Rice Breakthrough Aims to Prevent Fibrotic Diseases. The Magazine of Rice University, vol. 63, No. 3.
Kadler, K.E. (1996) Collagen fibril formation. Biochemical Journal, vol. 316, p. 1-11.
Kvist, A.J., Johnson, A.E., Mörgelin, M., Gustafsson, E., Bengtsson, E., Lindblom, K., Aszódi, A., Fässler, R., Sasaki, T., Timpi, R., Aspberg, A. (2006) Chondroitin Sulfate Perlecan Enhances Collagen Fibril Formation, Implications for Perlecan Chondrodysplasias. Journal of Biological Chemistry, vol. 281, No. 44, p. 33127-33139.
Kasavina, B.S., Rikhter, A.I., Zenkevich, G.D. (1961) The Effect of Chondroitin Sulfate (Chonsuridum) on collagen In Vivo. Bulletin of Experimental Biology and Medicine, vol. 51, No. 6, p. 718-720.
Nagaoka, T., Kaburagi, Y., Hamaguchi, Y., Hasegawa, M., Takehara, K., Steeber, D.A., Tedder, T.F., Sato, S. (2000) Delayed Wound Healing in the Absence of Intercellular Adhesion Molecule-1 or L-Selectin Expression. American Journal of Pathology, vol. 157, No. 1, p. 237-247.
Definition of “ulcer” from The Free Dictionary [online], [retrieved on Dec. 8, 2009]. Retrieved from the internet <http://medical-dictionary.thefreedictionary.com/ulcers>.
Peyton, B.D., Rohrer, M.J., Furman, M.I., Barnard, M.R., Rodino, L.J., Benoit, S.E., Hechtman, H.B., Valeri, R., Michelson, A.D. (1998) Patients with venous stasis ulceration have increased monocyte-platelet aggregation. Journal of Vascular Surgery, vol. 27, No. 6, p. 1109-1116.
Essentials of Glycobiology (1999) Edited by Varkit, A., Cummings, R., Esko, J., Freeze, H., Hart, G., Marth, J. Published by Cold Spring Harbor Laboratory Press, New York, p. 26-28.
Danielson, K. et al., Targeted Disruption of Decorin Leads to Abnormal Collagen Fibril Morphology and Skin Fragility. The Journal Cell Biology Feb. 10, 1997;136(3):729-743.
Hedbom, E. and Heinegard, D., Interaction of a 59-kDa Connective Tissue Matrix Protein with Ciollagen I and Collagen II. The Journal of Biological Chemistry Apr. 25, 1989; 264(12)6898-6905.
Svensson, L. et al., Fibromodulin-null Mice Have Abnormal Collagen Fibrils, Tissue Organization, and Altered Lumican Deposition in Tendon. The Journal of Biological Chemistry Apr. 2, 1999;274(14):9636-9647.
Vogel, K. et al., Specific Inhibition of Type I and Type II Collagen Fibrillogenesis by the Small Proteoglycan of Tendon. Biochem. J. Feb. 29, 1984;223:587-597.
Einbinder et al. “Separation of chondroitin sulphate from cartilage”J. Biol. Chem.(1950) 185:725-730.
Adebowale et al. “Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials”J. Am. Nutr. Assoc.(2000) 3:37-44.
Sugahara et al. “Structure and Function of Oversulfated Chondroitin Sulfate Variants: Unique Sulfation Patterns and Neuroregulatory Activities”Trends in Glycoscience and Glycotechnology(2000) 12(67):321-349.
Yamada et al. “Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate”Current Drug Discovery Technologies(2008) 5(4):289-301.
Steffensen et al., “Proteolytic events of wound-healing-coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules”, Crit. Rev. Oral. Biol. Med. (2001) 12(5): 373-398.
Arikawa-Hirasaw et al., “Perlecan is Essential for Cartilage and Cephalic Development,”Nature Genetics23:354-358 (1999).
Aviezer et al., “Perlecan, Basal Lamina Proteoglycan, Promotes Basic Fibroblast Growth Factor-Receptor Binding, Mitogenesis, and Angiogenesis,”Cell79:1005-1013 (1994).
Bengtsson et al., “The Leucine-Rich Repeat Protein PRELP Binds Perlecan and Collagens and May Function as a Basement Membrane Anchor,”The Journal of Biological Chemistry277(17):15061-15068 (2002).
Brown et al., “The C-Terminal Domain V of Perlecan Promotes β1 Integrin-Mediated Cell Adhesion, Binds Heparin, Nidogen and Fibulin-2 and Can Be Modified by Glycosaminoglycans,”Eur. J. Biochem250:39-46 (1997).
Costell et al., “Perlecan Maintains the Integrity of Cartilage and Some Basement Membranes,”The Journal of Cell Biology147(5):1109-1122 (1999).
Couchman et al., “Perlecan and Basement Membrane-Chondroitin Sulfate Proteoglycan (Bamacan) are Two Basement Membrane Chondroitin/Dermatan Sulfate Proteoglycans in the Engelbreth-Holm-Swarm Tumor Matrix,”The Journal of Biological Chemistry271(16):9595-9602 (1996).
Gonzalez et al., “A Novel Interaction Between Perlecan Protein Core and Progranulin,”The Journal of Biological Chemistry278(40):38113-38116 (2003).
Heinegard and Paulsson, “Structure and Metabolism of Proteoglycans,” Extracellular Matrix Biochemistry 1stEdition, Elsevier, Amsterdam, Chapter 8: 277-328 (1984).
Nicole et al., “Perlecan, the Major Proteoglycan of Basement Membranes, is Altered in Patients with Schwartz-Jampel Syndrome (Chondrodystrophic Myotonia),”Nature Genetics26:480-486 (2000).
Timpl and Brown, “Supramolecular Assembly of Basement Membranes,”BioEssays18(2):123-132 (1995).
Wight et al., “Proteoglycans” Cell Biology of Extracellular Matrix, Second Edition, Plenam Press, New York, Chapter 2: 45-78 (1991).
Powell, et al.; “Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation”; Journal of Vascular Surgery (1999); 30(5): 844-853.
Bocker, T. et al., Synthesis and properties of sulfated alkyl glycosides. Carbohydr Res. Jun. 16, 1992;230(2):245-56.
Edward, M. and Oliver, R.F., Changes in the synthesis, distribution and sulphation of glycosaminoglycans of cultured human skin fibroblasts upon ascorbate feeding. J Cell Sci. Nov. 1983;64:245-54.
Gilbert, M.E. et al., Chondroitin sulfate hydrogel and wound healing in rabbit maxillary sinus mucosa. Laryngoscope. Aug. 2004;114(8):1406-9.
Habuchi, O. et al., Enzymatic synthesis of chondroitin sulfate E by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase purified from squid cartilage. Anal Biochem. Nov. 15, 2002;310(2):129-36.
Integra™ website: http://www.integra-ls.com/products/?product=122 (Integra™ Bilayer Matrix Wound Dressing), [Retrieved from the internet on Nov. 12, 2007].
Kaji, T. et al., Characterization of chondroitin/dermatan sulfate proteoglycans synthesized by bovine retinal pericytes in culture. Biol Pharm Bull. Nov. 2004;27(11):1763-8.
Karamanos, N.K. et al., Isolation and chemical study of the glycosaminoglycans from squid cornea. Int J Biochem. 1991;23(1):67-72.
Kirker, K.R et al., Glycosaminoglycan hydrogels as supplemental wound dressings for donor sites. J Burn Care Rehabil. May-Jun. 2004;25(3):276-86. (Abstract).
Kirker, K.R. et al., Glycosaminoglycan hydrogel films as bio-interactive dressings for wound healing. Biomaterials. Sep. 2002;23(17):3661-71.
Kosir, M.A. et al., Matrix glycosaminoglycans in the growth phase of fibroblasts: more of the story in wound healing. J Surg Res. Jul. 2000;92(1):45-52.
Munakata, H. et al., Interaction between collagens and glycosaminoglycans investigated using a surface pla
Aspberg Anders
Heinegård Dick
Johnson Anna
Kvist Alexander
AnaMar AB
Goon Scarlett
Jiang Shaojia Anna
Wolf Greenfield & Sacks P.C.
LandOfFree
Use of chondroitin sulphate E (CS-E) for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of chondroitin sulphate E (CS-E) for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of chondroitin sulphate E (CS-E) for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659027